Summary The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium
(CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics …

Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Mass-spectrometry-based proteomic data on human tumors—combined with corresponding
multi-omics data—present opportunities for systematic and pan-cancer proteogenomic …

Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few
therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a …

Genomic analyses in cancer have been enormously impactful, leading to the identification of
driver mutations and development of targeted therapies. But the functions of the vast majority …

Abstract Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-
negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which …

Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers
characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs …

Clear cell renal cell carcinoma (ccRCC) is a common and aggressive subtype of renal
cancer. Here we conduct a comprehensive proteogenomic analysis of 232 tumor and …

Cancer driver events refer to key genetic aberrations that drive oncogenesis; however, their
exact molecular mechanisms remain insufficiently understood. Here, our multi-omics pan …